TET2 and chronic myelomonocytic leukemia: With this comes the ability to predict the risk of disease, such as the presence of TET2, SRSF2, and ASXL mutations pointing toward the development of CMML, or the poor prognosis of MDS/MPN NOS associated with TP53 mutations.